Midday movers: Affirm, Amazon, and More
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Amazon.com (AMZN) Mentioned Positively at Citi, Top Pick
November 29, 2023 7:57 AM ESTCiti analyst Ronald Josey reiterated a Buy rating and $177.00 price target on Amazon.com (NASDAQ: AMZN)
The analyst comments "Following our time at AWS and after hosting our 7th Annual Citi Cloud Forum with Citis Software Analysts Tyler Radke and Fatima Boolani, we... More
Amazon.com (AMZN) Mentioned Positively at Susquehanna
November 29, 2023 7:27 AM ESTSusquehanna analyst Shyam Patil reiterated a Positive rating and $185.00 price target on Amazon.com (NASDAQ: AMZN)
The analyst comments "Unveiling Amazon Q, an AI chatbot for enterprises. One of the key product announcements at this years re:Invent conference was a generative AI tool Amazon Q, a new AI-powered assistant designed for enterprises. The product, currently... More
Shopify (SHOP) holds an 'untenable valuation' - Piper Sandler
November 28, 2023 8:31 AM ESTShopify (NYSE: SHOP) shares were cut to Underweight from Neutral at Piper Sandler on Tuesday, with analyst Clarke Jeffries lowering the price target to $56 from $58 per share.
Jeffries said in a note that the firm decided to revisit its investment thesis... More
Teva Pharma 'uniquely positioned,' Jazz Pharmaceuticals set-up balanced - UBS
November 27, 2023 11:21 AM ESTInvestment bankUBS raised Teva Pharma (NYSE: TEVA) to Buy from Neutral and downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) to Neutral from Buy in separate notes to clients on Monday.
Analyst Ashwani Verma raised the TEVA price target to $13 from $11 per share, stating the brand transition is underway and launch... More
